Literature DB >> 30518503

CD19-directed CAR T cells gain traction.

Stephen J Schuster1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30518503     DOI： 10.1016/S1470-2045(18)30900-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  10 in total

Review 1.  T cell-engaging therapies - BiTEs and beyond.

Authors:  Maria-Elisabeth Goebeler; Ralf C Bargou
Journal:  Nat Rev Clin Oncol       Date:  2020-04-02       Impact factor: 66.675

2.  Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.

Authors:  Pei-Hsuan Chen; Mikel Lipschitz; Jason L Weirather; Caron Jacobson; Philippe Armand; Kyle Wright; F Stephen Hodi; Zachary J Roberts; Stuart A Sievers; John Rossi; Adrian Bot; William Go; Scott J Rodig
Journal:  JCI Insight       Date:  2020-06-18

3.  Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.

Authors:  Shao Weimin; Asimujiang Abula; Ding Qianghong; Wang Wenguang
Journal:  Cancer Biol Ther       Date:  2020-03-25       Impact factor: 4.742

Review 4.  State of the art in CAR T cell therapy for CD19+ B cell malignancies.

Authors:  Matthew J Frigault; Marcela V Maus
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 5.  Recent advances in CAR-T cell engineering.

Authors:  Ruihao Huang; Xiaoping Li; Yundi He; Wen Zhu; Lei Gao; Yao Liu; Li Gao; Qin Wen; Jiang F Zhong; Cheng Zhang; Xi Zhang
Journal:  J Hematol Oncol       Date:  2020-07-02       Impact factor: 17.388

6.  A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?

Authors:  Jie Zhang; Junlong Li; Qiufei Ma; Hongbo Yang; James Signorovitch; Eric Wu
Journal:  Adv Ther       Date:  2020-06-10       Impact factor: 3.845

Review 7.  Recent updates on CAR T clinical trials for multiple myeloma.

Authors:  Quande Lin; Juanjuan Zhao; Yongping Song; Delong Liu
Journal:  Mol Cancer       Date:  2019-11-05       Impact factor: 27.401

8.  Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.

Authors:  Heng Wei; Zeng Wang; Yi Kuang; Zhiguo Wu; Shasha Zhao; Zongliang Zhang; Hexian Li; Meijun Zheng; Nan Zhang; Cheng Long; Wenhao Guo; Chunlai Nie; Hui Yang; Aiping Tong
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

Review 9.  Targeted therapy of multiple myeloma.

Authors:  Shan Zhou; Renxi Wang
Journal:  Explor Target Antitumor Ther       Date:  2021-10-31

Review 10.  Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.

Authors:  Jason R Westin; Marie José Kersten; Gilles Salles; Jeremy S Abramson; Stephen J Schuster; Frederick L Locke; Charalambos Andreadis
Journal:  Am J Hematol       Date:  2021-08-13       Impact factor: 13.265
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.